Vera Therapeutics, Inc.
$35.66+4.2%1Y+51.4%
Mentions · last 7 days
62
Price updated 1h ago·X counts updated 4h ago
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $VERA.
Biotechnology
GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.
What this means for $VERA
Neutral — binary clinical-stage catalyst set is independent of the broader industry macro driver; pipeline readout timing is the company-specific event.
Top industry ETF
$IBBiShares Biotechnology ETF
+12.1%YTD
+50.1%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-5.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-85.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-13.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-84.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 10, 2026$-1.52$-1.58+3.8%
Q1 2026May 7, 2026$-1.69$-1.33-27.2%
Q4 2025Feb 26, 2026$-1.39$-1.34-3.7%
Q3 2025Nov 5, 2025$-1.26$-1.20-5.0%
Next earningsWed, Nov 4·consensus EPS $-1.61
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-1.52$-100.3M
Q1 FY26$0———$-1.69$-106.7M
Q4 FY25$0———$-1.39$-70.1M
Q3 FY25$0———$-1.26$-62.0M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$25.6M$21.5M – $27.8M-$6.25-$6.91 – -$5.668
FY27$234.9M$139.1M – $393.4M-$4.28-$5.08 – -$2.238
FY28$610.6M$249.3M – $930.5M-$0.40-$3.14 – $4.1110
FY29$1.1B$509.5M – $1.7B$3.02$0.99 – $5.335
FY30$1.5B$707.2M – $2.3B$6.03$1.98 – $10.635
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.37%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-5.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-13.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 58.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today7.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
3New insider — initial holdingsAug 53
AI summary
8-KOfficer or director changeJul 98-K — Item 5.02: Officer or director change
AI summary
8-KShareholder voteMay 268-K — Item 5.07: Shareholder vote
8-KOfficer or director changeMar 98-K — Item 5.02: Officer or director change
+ 16 other (7 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 routine 8-Ks) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Vera Therapeutics to Participate at Upcoming Investor ConferencesVera Therapeutics: FDA's eGFR Analysis Supports A Speculative BuyE. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $VERA on X in the last 7 days.